US6402683063
US6402683063
Nektar Therapeutics
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 60/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±122.8% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 1.3x as much as the broader market.
Beta (Market Relation)
1.27x
Above averageVolatility (5Y p.a.)
122.8% p.a.
5-Year HorizonMax Drawdown (5Y)
-97.6%
5-Year HorizonSharpe Ratio
-0.27
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -27.9% |
| 3 Years | 129.1% | -73.2% | 0.56 | +74.7% |
| 5 Years | 122.8% | -97.6% | -0.27 | -30.7% |
| 10 Years | 97.7% | -99.6% | -0.2 | -16.8% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (129.1%) is noticeably higher than the 5Y average (122.8%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (122.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.6% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
7 ISS Score: 7 / 10
Board Risk
7 ISS Score: 7 / 10
Short Ratio
8.82